Rebecca Spalding
Rebecca Spalding, a biotech reporter at Bloomberg News, has left the organization.
On Twitter, Spalding wrote, “I will have something new to say soon but for now, I’m reflecting fondly on the time I spent here and the wonderful colleagues I met here. I’m so proud to have started my journalism career at Bloomberg.”
Spalding was based on Boston. She has written about a drug with a $2 million price tag, a Harvard professor who made $400 million in an biotechnology IPO, Blackstone’s foray into drug development, and how Cambridge, Massachusetts, came to be a magnet for the industry.
She had been at Bloomberg for nearly four years and had previously interned at Forbes.
The Star Tribune is seeking an accomplished, motivated and versatile journalist and leader to shape…
The Deputy AME-Business is responsible for the development and planning of coverage on all Newsday…
CNBC.com managing editor Jeff McCracken announced Friday the following promotions: In San Francisco, Ari Levy has…
This Newsday reporter will cover Long Island’s commercial real estate market and the region’s evolving…
The New York Times is looking for a versatile editor to edit enterprise and feature…
International editor Matt Lamers is leaving Marijuana Business Daily. He has been there for seven years. Lamers…